Navigation Links
Clinical Data Presented on OrthoGlide(R) Medial Knee Implant
Date:11/28/2007

Advanced Bio-Surfaces releases data on minimally invasive alternative to

total knee replacement

MINNEAPOLIS, Nov. 28 /PRNewswire/ -- Advanced Bio-Surfaces, Inc. (ABS), announced today the availability of OrthoGlide Medial Knee Implant initial clinical data.

Data representing the first complete year of enrollment in the OrthoGlide clinical study was presented on November 10th, 2007 at the American College of Rheumatology's annual meeting in Boston, MA. The data was presented by William Arnold, M.D., Medical Director for ABS. "The OrthoGlide prospective clinical study has enrolled 92 patients with osteoarthritis of the medial compartment that met the inclusion criteria," said Dr. Arnold. "These patients would have been candidates for an invasive Total Knee Replacement (TKR) procedure."

A summary of the data includes 92 patients implanted at 6 approved sites in the United States. Fourteen of the enrolled patients have surpassed the one year implant anniversary. The demographics of the study group include an average age of 60 years, 52% male / 48% female and WOMAC Pain scores which improve from 35 pre-operatively to 72 at 6 months and 74 at one year post- operative. The most serious adverse event reported was the need to convert patients to either a unicompartmental knee or TKR. Nine OrthoGlide patients enrolled (10.2%) were converted, which is comparable to the 9% unicompartmental knee conversion rate at two years post-operative. Also important is the fact that only one patient out of 350 total implants (includes study and non-study patients) experienced a dislocation.

Dr. Arnold summarized the data by saying, "The pain relief experienced by the patients enrolled in this study, along with the return of knee function at one year is similar to TKR results but with a much less invasive procedure."

About Advanced Bio-Surfaces, Inc.

ABS is a privately held company dedicated to the development of innovative joint restoration products. The company's first product, the OrthoGlide Medial Knee Implant, is intended for the treatment of patients with moderate osteoarthritis of the medial compartment. It is securely implanted without bone cutting or rigid fixation, is expected to provide a more rapid recovery than TKR, a shorter hospital stay and no rehabilitation. The company received 510(k) clearance to market in February 2006 and 350 implants have been completed. For additional information contact ABS at 952.912.5400 or visit the website at http://www.advbiosurf.com.


'/>"/>
SOURCE Advanced Bio-Surfaces, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)...  Perrigo Company plc (NYSE, TASE: PRGO) today announced it ... Administration for hydrocodone bitartrate and homatropine methylbromide oral solution (syrup), ... bitartrate and homatropine methylbromide oral solution (syrup), 5 mg/1.5 mg ... cough in adults and children 6 years of age and ... were approximately $16 million.   ...
(Date:2/17/2017)... , Feb 17, 2017 Research and Markets has ... Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America , ... period 2015 through 2022. Also, a six-year historic analysis is provided for ...
(Date:2/17/2017)... 2017  In partnership with CitiHope , ... , The Jack Brewer Foundation (JBF Worldwide) ... dollars, worth of medicine to Innovating Health International ... a non-profit dedicated to treating chronic diseases and addressing women,s ... Haiti and providing these medicines ...
Breaking Medicine Technology:
(Date:2/17/2017)... TN (PRWEB) , ... February 17, 2017 , ... ... mobility has not kept pace. Enovate Medical has introduced an innovative workstation designed ... years of supporting nurses, the Encore Mobile EHR Workstation offers a lightweight, highly ...
(Date:2/17/2017)... Rancho Palos Verdes, CA (PRWEB) , ... February ... ... well-being, and emotional flow is Dr. Carol Francis' goals for each ... Federation Retreat Conference, Dr. Carol Francis will demonstrate five different brainwave tools which ...
(Date:2/17/2017)... ... February 17, 2017 , ... MAP ... today that Karen Pilley has been promoted to Chief Executive Officer. , ... healthcare paradigm – a shift that demands the transition from pay-for-service to pay-for-performance ...
(Date:2/17/2017)... ... February 17, 2017 , ... Top neuroendocrine cancer doctors, nurses and specialists ... from February 21 - 23 in Beaver Creek, CO. It was announced today by ... second year in Beaver Creek, hosting over 60 faculty members and addressing unmet needs ...
(Date:2/16/2017)... (PRWEB) , ... February 17, 2017 , ... Teaching nursing ... (ACE) program, now in development. ACE.P (pediatrics) is being created with the support of ... Care of Vulnerable Populations , ACE.P will address what has been identified as a ...
Breaking Medicine News(10 mins):